Chronic Obstructive Pulmonary Disease (COPD) is a lung condition that makes it hard to breathe. This study is looking at the long-term safety of a medicine called Itepekimab, which is given by injection under the skin (subcutaneous or SC) every 2 weeks (Q2W) or every 4 weeks (Q4W). The study aims to see if the medicine is safe and how well it works after the main treatment period in past studies.

The study is double blind, meaning that neither the participants nor the researchers know who is getting the real medicine or a placebo (a fake medicine). It's important to know this study will last up to 72 weeks, with treatment lasting up to 52 weeks and follow-up for 20 weeks. Participants will need to visit the study site 7 times and have 5 phone check-ins. Only people who finished prior Itepekimab studies can join. If you were diagnosed with cancer (except some skin cancers) or had serious infections during the past study, you cannot participate.

• The study will last up to 72 weeks.
• 7 in-person visits and 5 phone calls are required.
• Only those who completed previous studies can join.